Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma / ESMO

esmo - Findings from the ZSAB-neoGOLP study

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #clinicaltrials

Nieves Martinez Lago: Time Toxicity in First-Line BTC Treatment

8 hrs / oncodaily

Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma

17 hrs / esmo

Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma: ZSAB-neoGOLP Trial

5 days / oncodaily

Monday, March 16, 2026, 3:21 am / permalink 20797 / 3 stories in 17 hrs

NRG-LU005 Trial: Atezolizumab Plus Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer / OncoDaily

oncodaily - A major international clinical trial, NRG-LU005, has provided important new insight into how immunotherapy should be used in limited-stage small cell lung cancer (SCLC). While immune checkpoint inhibitors have significantly […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch

Misty Dawn Shields: ISL1 Neuroendocrine Subtype in SCLC Offers Durable Response to Lurbinectedin

4 hrs / oncodaily

Tislelizumab Plus Chemotherapy in ES-SCLC Delivers Sustained Survival Benefit in Long-Term Follow-Up of RATIONALE-312

7 hrs / oncodaily

NRG-LU005 Trial: Atezolizumab Plus Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer

31 hrs / oncodaily

Trial finds immunotherapy did not improve survival when added to chemoradiotherapy for small cell lung cancer

3 days / medicalxpress

Monday, March 16, 2026, 12:23 am / permalink 20789 / 4 stories in 20 hrs

A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices / Medical Express

medicalxpress - A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Re…

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch

Dark sweet cherries may help slow aggressive breast cancer, mouse study suggests

36 hrs / medicalxpress

Oluwasanmi Ajagbe: Lay Notes About Triple Negative Breast Cancer

37 hrs / oncodaily

A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices

3 days / medicalxpress

How a Reproductive Gene Could Hold the Key to Treating Triple Negative Breast Cancer – ICR

4 days / oncodaily

Saturday, March 14, 2026, 11:21 pm / permalink 20776 / 4 stories in 45 hrs

Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision / MedCity

Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #healthcarefinance

Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision

7 days / medcitynews / Frank Vinluan

GSK licenses linerixibat for liver disease itch to Alfasigma for $300M upfront

7 days / endpoints / Reynald Castaneda

Saturday, March 14, 2026, 8:21 pm / permalink 20771 / 2 stories in 2 days

Roche’s big hope breast cancer drug fails in crucial first-line trial / Endpoints

Elizabeth Cairns / endpoints - Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The persevERA ...

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch

DARE Trial: Phase II Study of ctDNA-Guided Intervention in ER+/HER2− Early Breast Cancer — Investigator Perspective

7 hrs / oncodaily

BRCA2-Driven Breast Cancer May Follow A Different Resistance Path On CDK4/6 Inhibitors

17 hrs / oncodaily

Natera Announces Webinar on PALLAS and LEADER Studies in Early Breast Cancer

2 days / oncodaily

1 in 3 Americans make financial trade-offs to afford healthcare: Gallup

4 days / beckershospitalreview / Kristin Kuchno

Roche’s big hope breast cancer drug fails in crucial first-line trial

7 days / endpoints / Elizabeth Cairns

Saturday, March 14, 2026, 7:21 pm / permalink 20770 / 5 stories in 2 days

Antonio Calles: RECITE Trial Findings on Romiplostim for Chemotherapy-Induced Thrombocytopenia / OncoDaily

oncodaily - Antonio Calles, Medical Oncologist at Hospital General Universitario Gregorio Marañón and faculty member of the Lung and Other Thoracic Tumours faculty group of the ESMO, shared a post by NEJM, […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch

Antonio Calles: RECITE Trial Findings on Romiplostim for Chemotherapy-Induced Thrombocytopenia

2 days / oncodaily

Romiplostim prevents serious side effect of chemotherapy in phase 3 trial

4 days / medicalxpress

Saturday, March 14, 2026, 12:23 pm / permalink 20760 / 2 stories in 2 days

Grail names new CEO as Bob Ragusa retires / Endpoints

Jared Whitlock / endpoints - Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman. The cancer screening company said the move was the culmination of long-term succession ...

#healthcare #biotech #medicaldevices #oncology #healthcarefinance #cancerresearch

Baxter CFO to exit, interim leader named

6 hrs / beckershospitalreview / Madeline Scheetz

WVU foundation CEO to retire

6 hrs / beckershospitalreview / Kristin Kuchno

Blood tests for cancer? We're still a way off

26 hrs / medicalxpress

Nicholas Hornstein: GRAIL Has Had a Strange Life as a Company

3 days / oncodaily

Grail names new CEO as Bob Ragusa retires

3 days / endpoints / Jared Whitlock

Saturday, March 14, 2026, 4:21 am / permalink 20744 / 5 stories in 2 days

Ipsen pulls cancer drug Tazverik from market over safety risks / Endpoints

Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda #productrecall #oncology #cancerresearch

BioMarin halts Phase 2 Voxzogo dosing in certain patients over safety concern

6 hrs / endpoints / Nicole DeFeudis

Cancer drug pulled from US market

6 days / beckershospitalreview / Paige Twenter

Ipsen pulls cancer drug Tazverik from market over safety risks

7 days / endpoints / Nicole DeFeudis

Saturday, March 14, 2026, 12:23 am / permalink 20738 / 3 stories in 2 days

FDA Transparency Push Expands to Monitoring Safety of Vaccines and Other Regulated Products / MedCity

Frank Vinluan / medcitynews - The FDA said consolidating safety reporting into a single platform, the Adverse Event Monitoring System (AEMS), will increase transparency and reduce costs. But like the legacy systems it replaces, AEMS reports are unverified so causation and frequency of…

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #fda #vaccinesafety #digitalhealth #animalhealth

CDC panel advises tracking COVID-19 vaccine injuries

3 hrs / beckershospitalreview / Ella Jeffries

Confidential Report Calls for Sweeping Changes to Track Covid Vaccine Harms

27 hrs / nytimes / Apoorva Mandavilli and Sheryl Gay Stolberg

The AI Adverse Event Problem Nobody Is Talking About

3 days / beckershospitalreview / Allie Woldenberg

FDA Transparency Push Expands to Monitoring Safety of Vaccines and Other Regulated Products

4 days / medcitynews / Frank Vinluan

FDA to unify agency’s ‘fragmented’ safety surveillance system

4 days / healthcaredive / Kristin Jensen

FDA launches single adverse event platform

5 days / beckershospitalreview / Elizabeth Gregerson

FDA merges adverse event trackers into one database

5 days / endpoints / Max Bayer

Thursday, March 12, 2026, 5:23 pm / permalink 20659 / 7 stories in 4 days

Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors / Science Translational Medecine

Torahito A. Gao, Ryan M. Shih, Justin D. Clubb, Shao-Hsi Hung, Tanya Singh, Laura B. James-Allan, Ga / science - Science Translational Medicine, Volume 18, Issue 839, March 2026.

#pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch

Universal, ready-to-use immunotherapy detects and destroys endometrial cancer in preclinical tests

3 hrs / medicalxpress

Bernard A. Fox: Cancer Immunotherapy Pioneer John Haanen Receives ITOC12 Lifetime Achievement Award

4 hrs / oncodaily

Agenus Reports 2025 Progress: BOT+BAL Immunotherapy Advances to Phase 3 with Global Early Access Programs

4 hrs / oncodaily

Kristen Hege: Presenting “CAR-T Lessons for Next-Gen Cell Therapies” at SITC Spring Scientific

8 hrs / oncodaily

LATAM MasterCourse 2026 in Pediatric Oncology Held in Montevideo

35 hrs / oncodaily

Al-Ola A Abdallah: BiTE vs CAR-T in Myeloma at National ICE-Congress 2026

37 hrs / oncodaily

Katy Beckermann: Can CAR-T Innovation Expand Into Solid Tumors?

2 days / oncodaily

Karamvir Yadav: Can Anti-Angiogenic Therapy Enhance Immunotherapy in NSCLC?

2 days / oncodaily

Multi-cytokine scaffold helps CAR-T cells fight cancer and HIV for longer

3 days / medicalxpress

Dual targeting approach improves immunotherapy response in glioblastoma

3 days / medicalxpress

Tuning T cells' cancer-killing power via an engineered hydrogel platform

4 days / medicalxpress

Anchoring a key immune molecule makes T cells hit harder

4 days / medicalxpress

Targeted treatments plus engineered immune cells may slow early spread of triple‑negative breast cancer, study reveals

6 days / medicalxpress

Yakup Ergün: Exploring New Therapy for TNBC Brain Metastases

7 days / oncodaily

Biomimetic platform developed to enhance CAR T cell therapy against leukemia

7 days / medicalxpress

Glen Clack: Are Cell Therapies Too Expensive and Too Toxic to Scale?

7 days / oncodaily

Engineered CAR-T cells block key protein to break solid tumors' immune shield

12 days / medicalxpress

Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors

12 days / science / Torahito A. Gao, Ryan M. Shih, Justin D. Clubb, Shao-Hsi Hung, Tanya Singh, Laura B. James-Allan, Ga

Monday, March 9, 2026, 4:22 am / permalink 20364 / 18 stories in 7 days

Elizabeth McKenna: New Cancer Grand Challenges Teams Announced / OncoDaily

oncodaily - Elizabeth McKenna, Executive Editor of Cancer Discovery, shared a post on X: “The new Cancer Grand Challenges teams have just been announced! Read about the teams tackling cancer avoidance, mechanisms […]

#healthcare #biotech #drugdevelopment #oncology #healthcarefinance #cancerresearch #researchfunding

Lantheus Secures Two FDA Milestones in Four Days: Lutathera Radioequivalent and PSMA PET Upgrade

2 days / oncodaily

Health Canada Approves Selumetinib (Koselugo) for Adult NF1 Plexiform Neurofibromas

2 days / oncodaily

Mark Lawler: Building New Academic Partnerships with Westfield State University

2 days / oncodaily

Preparing to Welcome Researchers to the SIOG Masterclass in Florida – SIOG

2 days / oncodaily

Daniel Stover: New Insights into Resistance in Breast Cancer from Nature Study

3 days / oncodaily

Olubukola Ayodele: Why Cancer Care Must Go Beyond Tumor-Focused Medicine